Between Bedside and Bench | Published:

How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy

Nature Medicine volume 19, pages 822824 (2013) | Download Citation

This article has been updated

Discerning which mediators drive pathogenesis in chronic inflammatory diseases can be complex: immune cells can release various pathogenic cytokines, and numerous cytokines may either cause one specific disease or many. Human validation and mechanistic studies will be necessary to identify the key immune cells and cytokines for a given inflammatory disorder and to pinpoint which cytokine might be the appropriate target for tackling each disease. In 'Bedside to Bench', Georg Schett et al. discuss how human trials targeting different cytokines suggest the existence of a hierarchical framework of cytokines that defines groups of chronic inflamatory diseases rather differently from the homogenous molecular disease pattern previously assumed. In 'Bench to Bedside', Vijay Kuchroo and Dominique Baeten peruse the role of interleukin-17A as drug target in several autoimmune diseases to highlight how success in the clinic will need understanding of pathogenic pathways and the immunological and tissue context of each inflammatory disease.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 16 July 2013

     In the version of this article initially published, the cell at the intersection of IL-12/23 and ulcerative colitis was light green, when it should have been gray. The cell at the intersection of IL-12/23 and Crohn's disease was gray, when it should have been light green. The errors have been corrected in the HTML and PDF versions of the article


  1. 1.

    & N. Engl. J. Med. 365, 2205–2219 (2011).

  2. 2.

    et al. Brain 123, 2005–2019 (2000).

  3. 3.

    et al. Gastroenterology 136, 257–267 (2009).

  4. 4.

    et al. Gastroenterology 126, 989–996 (2004).

  5. 5.

    , & J. Clin. Invest. 121, 3375–3383 (2011).

  6. 6.

    et al. J. Exp. Med. 163, 1433–1450 (1986).

  7. 7.

    et al. J. Exp. Med. 169, 2257–2262 (1989).

  8. 8.

    N. Engl. J. Med. 364, 443–452 (2011).

  9. 9.

    , & Nat. Med. 8, 567–573 (2002).

  10. 10.

    Nat. Med. 13, 242–244 (2007).

  11. 11.

    et al. N. Engl. J. Med. 367, 1519–1528 (2012).

  12. 12.

    et al. Gut 61, 1693–1700 (2012).

  13. 13.

    et al. Lancet published online, (13 June 2013).

  14. 14.

    , , , & Ann. Rheum. Dis. 72 Suppl. 2, ii111–ii115 (2013).

  15. 15.

    , & Drug Discov. Today 10, 1503–1519 (2005).

  16. 16.

    , , , & Nat. Med. 18, 66–70 (2012).

Download references

Author information


  1. Georg Schett is in the Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany.

    • Georg Schett
  2. Dirk Elewaut is in the Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.

    • Dirk Elewaut
  3. Iain B. McInnes is at the College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

    • Iain B. McInnes
  4. Jean-Michel Dayer is in the Faculty of Medicine, University of Geneva, Geneva, Switzerland.

    • Jean-Michel Dayer
  5. Markus F. Neurath is in the Department of Internal Medicine 1, University of Erlangen-Nuremberg, Erlangen, Germany.

    • Markus F. Neurath


  1. Search for Georg Schett in:

  2. Search for Dirk Elewaut in:

  3. Search for Iain B. McInnes in:

  4. Search for Jean-Michel Dayer in:

  5. Search for Markus F. Neurath in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Georg Schett.

About this article

Publication history



Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing